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Antituberculosis drug-induced hepatitis -
the dangers oJ rechallenge
To the Editor: There has been concern in our hospital about the
issue of antituberculosis drug-induced hepatitis and the dangers of
rechallenge. After a meeting between interested parties from
Groote Schuur and Brooklyn Chest hospitals, the following report
was fonnulated, which may be of interest to readers.
Approximately 0,3% of patients on commonly used antituber-
culosis therapy (streptomycin, isoniazid, pyrazinamide and rif-
ampicin) develop drug-induced hepatitis, most often within 3
months of starting treatment.' In descending order of probability,
the most likely offending agents are pyrazinamide, rifampicin and
isoniazid. Streptomycin is not likely to be implicated in this
problem.
The diagnosis of drug-induced hepatitis is made on clinical and
biochemical grounds. The patient is usually ill and may develop
jaundice, fever, nausea and right upper quadrant pain, and the
results of liver function tests are abnormal (confirmed on two
occasions). For this purpose an abnormal result is considered to be
an aspartate aminotransferase or alanine aminotransferase value
more than 3 times the upper limit of normal, an alkaline phospha-
tase level more than 1,5 times the upper limit of normal, or a
bilirubin level more than 2 times the upper limit of norma1.2
Transient mild elevation of these values is not uncommon during
the initial period of antituberculosis therapy, typically does nor
cause symptoms, and should not be confused with drug-induced
hepatitis. Other causes of hepatitis should be carefully sought, e.g.
alcohol and other hepatotoxic drugs, or hepatic enzyme-inducers
such as anticonvulsants. Viral hepatitis should be considered.
Once the diagnosis of drug-induced hepatitis is made, all anti-
tuberculosis therapy should be stopped until clinical and bio-
chemical recovery takes place. The issue of substitution or drug
rechallenge must then be considered. Deaths have been reported
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after patients have been rechallenged with drugs that have pre-
viously induced hepatitis. U As a result, a careful risk/benefit
assessment is mandatory. Care should be taken that the diagnosis
of tuberculosis is firmly established before continuing with therapy.
Rechallenge should not be considered without the advice of a
regional expert on tuberculosis therapy.
Since there are alternative agents, it is recommended that
patients should be rechallenged only if the tuberculosis is con-
sidered to be of such severity that this dangerous step is essential.
(Certain authorities would go so far as to say that it should only be
done if the tuberculosis is considered to be potentially fatal.) In
that event, the precautions outlined below should be strictly
adhered to. An alternative therapeutic regimen could be strepto-
mycin, ethambutol and ethionamide.
In severe tuberculosis (e.g. tuberculous meningitis or miliary
tuberculosis) the risk of the disease may be more serious than the
risk of drug-induced hepatitis. In this event it may be necessary to
rechallenge with one or more drugs. The following regimen is
recommended at Groote Schuur Hospital:
I. Additional advice must be sought from the University Liver
Clinic or the Clinical Pharmacology Unit.
2. The patient must be admined to hospital and monitored
closely, and informed consent must be obtained.
3. The following drugs could be used (after fulfilling the above
two recommendations): (i) streptomycin; (ii) ethambutol or
ethionamide (as new drugs); and (iiz) isoniazid (or rifampicin)
rechallenge.
It is recommended that rechallenge be carried out by giving
once only a quarter of a single dose of the drug and monitoring
the patient's clinical state closely. Liver function tests should be
performed at 6, 24, 48 and 96 hours. If the test dose is well
tolerated, the full dose could be given for 3 days and the patient
monitored daily for 4 days and again at I week. If there are no
problems, continuation at full dosage is justified.2
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The patient should be carefully monitored during the rest of his
antituberculosis therapy if rechallenged. The most important aspect
of this monitoring is the patient's clinical condition, in addition to
his or her reporting any untoward effecrs.
In conclusion, it should be emphasized that rechallenge in
drug-induced hepatitis is dangerous. It is recommended that
whenever possible patients should not be rechallenged. Should
rechallenge be considered essential this should only be done in a
major hospital and by experts in the management of fulminant
hepatic failure.
We would like to thank Professors P. I. Folb and R. E. Kirsch
and Drs A. Cavvadas, D. J. M. Jenkin, L. Pilkingron, A. H.
Robins and J. L. Straughan for participating in the meeting and
for their contribution to the report.
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Problems O'l{er death certificates
To the Editor: In the editorial entitled 'The death certificate -
fact or fiction?'1 'attention was drawn to the results of a recent
American autopsy study which indicated that in 29% of cases there
was major disagreement on the underlying causes of death.2 Other
reports indicating similar findings have been publishedY In
South Africa, the vital statistics of Africans have been labelled 'a
black hole'.5
Recently we have been studying 50% survival times of series of
black cancer patients in Soweto, as diagnosed at Baragwanath
Hospital. 6 When we investigated the extent to which the cause of
death (known to us) correlated with death certification data as
recorded at the Johannesburg City Health Department, it trans-
pired that certification was correct for only 38 of 65 blacks with
known breast cancer. Conversely, of 64 deaths certified as from
breast cancer, 44 were verified from records at Baragwanath
Hospital. On attempting to visit the remaining 20 patients' relatives
to enquire about antecedent medical attention, in only half of the
few cases in which satisfactory information was provided was
there a measure of certainty about the diagnosis. Hence, breast
cancer (and probably other cancers) is being both undercertified
and overcertified (as also reported for stomach cancer in the UK3).
Crucial local points to be taken into reckoning are: (i) in Johannes-
burg over a quarter of total death certificates of blacks are signed
by police'as from 'natural causes'; and (iz) a variable proportion of
the deceased are listed as dying from 'other causes'. In Pretoria in
1981,40% of deaths of those aged over 5 years were thus listed.7
This unsatisfactory situation confirms the urgent need for the
recently inaugurated National Cancer Registry,S based at this
Institute. Although initially it will be a pathology-based registry,
it will subsequently include clinically diagnosed tumours and
hence in time will provide much needed information on inter-
ethnic incidences of particular cancers.
Although our enquiries on death certificates are still in progress,
the 'situation depicted is alarming. We next looked into intercity
variability in inter-ethnic rates of death from cancer. Marked
differences are apparent in crude rates. Among blacks, in 1983 the
crude mortality rate for total cancer was far higher in Cape Town9
than in Durban. 1O For the coloured population, the crude death
rate for bronchial and lung cancer in Cape Town9 was roughly
double that in Durban. lo
We comment as follows:
I. To preserve balance it must be reiterated that in Western
populations numerous investigations have revealed major discre-
pancies between known and certified causes of death.2-~ Since no
examination of this type appears to have been made on any
population in South Africa, enquiries are obviously desirable.
Understandably, authoritative opinion overseas is urging greater
care in the filling in of death certificates:' II
2. When reporting cancer mortality among blacks (or similar
populations), sources of error must be detailed, as urged by
others.s
3. Although interregional differences in cancer mortality rates
(as in the UKI2) are well recognized, it would be profitable to look
more closely into the validity of our intercity differences.
4. Because of the uncertainties described, restraint must be
exercised (especially by enthusiasts, including ourselves) over
maintaining that this or that mortality rate for a particular cancer
is extremely low, or the converse. In this respect mortality rates
from cancer in developing populations as listed by the Segi
Institute 13 must be interpreted with reserve.
We are grateful to Professor C. Isaacson, Head of the Depart-
ment of Anatomical Pathology, SAIMR, for permission to use the
records at Baragwanath Hospital, and to Professor B. R. Richards
and Mrs Shirley Pryer, of the City Health Department, for death
certificate information. Help was given by Mrs M. Kadwa, M.
Verardi and D. Siwedi. The cancer survival studies are being
supported by a grant from the Chairman's Fund of Anglo-
American and De Beers.
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Raised carcino-embryonic antigen levels
To the Editor: Recently an increasing number of patients have
been referted to us for investigation of slightly raised carcino-
embryonic antigen (CEA) levels. The CEA level is often measured
to 'exclude' colorectal carcinoma in patients complaining of non-
specific abdominal pain. These patients arrive with the knowledge
that the 'cancer test' performed on them was positive and therefore
demand a full diagnostic work-up, including barium enema exami-
nation and colonoscopy.
The circulating blood level of CEA has not fulfilled its initial
promise as a sensitive and specific biological marker for the
detection of colorecral cancer. Elevated CEA levels occur in a wide
variety of benign conditions such as liver disease, ulcerative colitis,
Crohn's disease and pulmonary infections and also in other
malignant conditions such as carcinoma of the pancreas, breast,
liver or lung. Elevated levels have also been found in heavy
cigarette smokers. Estimation of the CEA level is not mentioned
as a screening test for colorectal cancer by the American Cancer
Society. I The unselecred use of CEA measurements in patients
with minimal abdominal symptoms will result in what we have
